| 101 | 16503991 | Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size. | Cardiovasc Diabetol | 2006 Feb 17 |
1 |
| 102 | 16629647 | Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease. | Liver Int | 2006 May |
2 |
| 103 | 16648553 | Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. | Mol Cancer Ther | 2006 Apr |
4 |
| 104 | 16648571 | Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. | Mol Cancer Ther | 2006 Apr |
7 |
| 105 | 16648572 | Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. | Mol Cancer Ther | 2006 Apr |
3 |
| 106 | 16697956 | Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. | Cancer Cell | 2006 May |
2 |
| 107 | 16984730 | Endothelin receptor A blockade enhances taxane effects in prostate cancer. | Neoplasia | 2006 Sep |
3 |
| 108 | 16997913 | Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. | Proc Natl Acad Sci U S A | 2006 Oct 3 |
2 |
| 109 | 17016430 | A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. | Oncogene | 2007 Apr 5 |
9 |
| 110 | 17032313 | Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma. | Cancer Sci | 2006 Dec |
2 |
| 111 | 17064063 | Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | J Med Chem | 2006 Nov 2 |
1 |
| 112 | 17097553 | Restoring cancer's death sentence. | Cancer Cell | 2006 Nov |
3 |
| 113 | 17097561 | The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. | Cancer Cell | 2006 Nov |
12 |
| 114 | 17098412 | Proteins modified with DNAzymes or aptamers act as biosensors or biosensor labels. | Biosens Bioelectron | 2007 May 15 |
2 |
| 115 | 17167119 | Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. | J Am Soc Nephrol | 2007 Jan |
1 |
| 116 | 17172851 | Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. | Cell Cycle | 2006 Dec |
4 |
| 117 | 17173063 | 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. | Oncogene | 2007 Jun 7 |
2 |
| 118 | 17189418 | Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. | Clin Cancer Res | 2006 Dec 15 |
5 |
| 119 | 17197188 | 4-amino-5-aryl-6-arylethynylpyrimidines: structure-activity relationships of non-nucleoside adenosine kinase inhibitors. | Bioorg Med Chem | 2007 Feb 15 |
1 |
| 120 | 17200714 | Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. | J Clin Invest | 2007 Jan |
3 |
| 121 | 17209055 | ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. | Blood | 2007 Apr 15 |
6 |
| 122 | 17234790 | Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. | Cancer Res | 2007 Jan 15 |
25 |
| 123 | 17255285 | The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. | Clin Cancer Res | 2007 Jan 15 |
2 |
| 124 | 17283153 | Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. | Cancer Res | 2007 Feb 1 |
13 |
| 125 | 17308113 | Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. | Cancer Res | 2007 Feb 15 |
1 |
| 126 | 17320823 | Platelet-activating factor antagonist (ABT-491) decreases neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury. | Brain Res | 2007 Apr 27 |
2 |
| 127 | 17343372 | Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. | J Med Chem | 2007 Apr 5 |
1 |
| 128 | 17384534 | ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. | Cancer Biol Ther | 2007 Mar |
3 |
| 129 | 17388305 | Reactions of 2,2'-azinobis-(3-ethylbenzthiazoline-6-sulfonate) dianion, ABTS2-, with *OH, (SCN)2*-, and glycine or valine peroxyl radicals. | J Phys Chem A | 2007 Mar 22 |
3 |
| 130 | 17409392 | Targeting multiple arms of the apoptotic regulatory machinery. | Cancer Res | 2007 Apr 1 |
9 |
| 131 | 17473206 | ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. | Clin Cancer Res | 2007 May 1 |
4 |
| 132 | 17505006 | Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. | Clin Cancer Res | 2007 May 15 |
1 |
| 133 | 17508927 | Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737. | Curr Top Med Chem | 2007 |
2 |
| 134 | 17536015 | Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. | Blood | 2007 Sep 15 |
1 |
| 135 | 17551310 | A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. | Am J Clin Oncol | 2007 Jun |
2 |
| 136 | 17554384 | BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. | Leukemia | 2007 Aug |
3 |
| 137 | 17572662 | Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. | Cell Death Differ | 2007 Sep |
2 |
| 138 | 17587812 | Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis. | Cells Tissues Organs | 2007 |
1 |
| 139 | 17662959 | Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. | Biochem Pharmacol | 2007 Oct 15 |
1 |
| 140 | 17688235 | Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. | Int J Cancer | 2007 Dec 1 |
1 |
| 141 | 17943175 | Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. | Leukemia | 2008 Jan |
9 |
| 142 | 18028486 | ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. | Br J Haematol | 2008 Jan |
7 |
| 143 | 18085673 | Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2008 Jun |
3 |
| 144 | 18089817 | Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. | Cancer Res | 2007 Dec 15 |
3 |
| 145 | 18096134 | Differences in motilin receptor desensitization after stimulation with motilin or motilides are due to alternative receptor trafficking. | Biochem Pharmacol | 2008 Mar 1 |
2 |
| 146 | 18160102 | In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. | Leuk Res | 2008 Jul |
2 |
| 147 | 18160428 | Bcl-xL inhibitor ABT-737 reveals a dual role for Bcl-xL in synaptic transmission. | J Neurophysiol | 2008 Mar |
2 |
| 148 | 18173118 | [Characterization of plant phenolic compounds by cyclic voltammetry]. | Prikl Biokhim Mikrobiol | 2007 Nov-Dec |
1 |
| 149 | 18376143 | Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage. | Cancer Biol Ther | 2008 Jun |
3 |
| 150 | 18381439 | Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. | Cancer Res | 2008 Apr 1 |
1 |